Javier Pinilla-Ibarz

Summary

Affiliation: H. Lee Moffitt Cancer Center and Research Institute
Country: USA

Publications

  1. ncbi request reprint Modern approaches to treating chronic myelogenous leukemia
    Javier Pinilla-Ibarz
    Department of Malignant Hematology, 12902 Magnolia Drive, MRC 3E 3056H, Tampa, FL 33612, USA
    Curr Oncol Rep 10:365-71. 2008
  2. ncbi request reprint Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
    Javier Pinilla-Ibarz
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, U S A
    Anticancer Res 35:6355-64. 2015
  3. ncbi request reprint Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist
    Javier Pinilla-Ibarz
    Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 22:7-16. 2015
  4. pmc Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia
    Julio C Chavez
    H Lee Moffitt Cancer and Research Institute, Division of Malignant Hematology, and University of South Florida, Tampa, FL, USA
    Core Evid 8:37-45. 2013
  5. pmc Role of ofatumumab in treatment of chronic lymphocytic leukemia
    Marays Veliz
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    J Blood Med 2:71-7. 2011
  6. doi request reprint The expanding options for front-line treatment in patients with newly diagnosed CML
    Javier Pinilla-Ibarz
    H Lee Moffitt Cancer Center and Research Institute, 13131 Magnolia Drive, 3 East, Rm 3056H, Tampa, FL 33612, USA
    Crit Rev Oncol Hematol 84:287-99. 2012
  7. ncbi request reprint The biological basis for immunotherapy in patients with chronic myelogenous leukemia
    Javier Pinilla-Ibarz
    Department of Malignant Hematology at the H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Control 16:141-52. 2009
  8. ncbi request reprint New agents in the treatment of chronic myelogenous leukemia
    Javier Pinilla-Ibarz
    Division of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Natl Compr Canc Netw 7:1028-37. 2009
  9. ncbi request reprint Chronic lymphocytic leukemia: putting new treatment options into perspective
    Javier Pinilla-Ibarz
    Malignant Hematology Division, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 17:4-15; quiz 16. 2010
  10. doi request reprint Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications
    Javier Pinilla-Ibarz
    Malignant Hematology Division, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Cancer 117:688-97. 2011

Collaborators

Detail Information

Publications50

  1. ncbi request reprint Modern approaches to treating chronic myelogenous leukemia
    Javier Pinilla-Ibarz
    Department of Malignant Hematology, 12902 Magnolia Drive, MRC 3E 3056H, Tampa, FL 33612, USA
    Curr Oncol Rep 10:365-71. 2008
    ..As our understanding of CML continues to grow, the repertoire of drugs available for successful treatment also increases. The following review discusses the current and future therapies for CML...
  2. ncbi request reprint Long-term BCR-ABL1 Tyrosine Kinase Inhibitor Therapy in Chronic Myeloid Leukemia
    Javier Pinilla-Ibarz
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, U S A
    Anticancer Res 35:6355-64. 2015
    ....
  3. ncbi request reprint Chronic Lymphocytic Leukemia in the Elderly, Which Investigations Are Necessary: A Map for the Practicing Oncologist
    Javier Pinilla-Ibarz
    Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 22:7-16. 2015
    ..Although chemoimmunotherapy is the frontline therapy for fit CLL patients who can tolerate the therapy, many elderly patients cannot tolerate such intense therapy...
  4. pmc Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia
    Julio C Chavez
    H Lee Moffitt Cancer and Research Institute, Division of Malignant Hematology, and University of South Florida, Tampa, FL, USA
    Core Evid 8:37-45. 2013
    ..Recent studies showing the benefit of combination therapy using ibrutinib, monoclonal antibodies, and chemoimmunotherapy are also discussed...
  5. pmc Role of ofatumumab in treatment of chronic lymphocytic leukemia
    Marays Veliz
    H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    J Blood Med 2:71-7. 2011
    ..Combination studies are being conducted to enhance the therapeutic efficacy of ofatumumab. This paper reviews some of the key clinical studies that led to approval of ofatumumab, and future directions...
  6. doi request reprint The expanding options for front-line treatment in patients with newly diagnosed CML
    Javier Pinilla-Ibarz
    H Lee Moffitt Cancer Center and Research Institute, 13131 Magnolia Drive, 3 East, Rm 3056H, Tampa, FL 33612, USA
    Crit Rev Oncol Hematol 84:287-99. 2012
    ..With continued advances, it is conceivable that the ultimate goal - a cure for CML - is in our sights...
  7. ncbi request reprint The biological basis for immunotherapy in patients with chronic myelogenous leukemia
    Javier Pinilla-Ibarz
    Department of Malignant Hematology at the H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Control 16:141-52. 2009
    ..Despite the success of the tyrosine kinase inhibitors (TKIs) in this disease, CML remains incurable. Only allogeneic bone marrow transplantation can provide long-term eradication of CML...
  8. ncbi request reprint New agents in the treatment of chronic myelogenous leukemia
    Javier Pinilla-Ibarz
    Division of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    J Natl Compr Canc Netw 7:1028-37. 2009
    ..This article provides an overview of novel targeted agents available for CML...
  9. ncbi request reprint Chronic lymphocytic leukemia: putting new treatment options into perspective
    Javier Pinilla-Ibarz
    Malignant Hematology Division, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 17:4-15; quiz 16. 2010
    ..Other agents recently approved and/or being tested, such as ofatumumab, flavopiridol, and lenalidomide, are demonstrating activity in the relapsed setting...
  10. doi request reprint Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications
    Javier Pinilla-Ibarz
    Malignant Hematology Division, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Cancer 117:688-97. 2011
    ..As more long-term data become available for newer TKIs, the definition of intolerance in the context of CML treatment will continue to evolve to maximize the likelihood of durable responses and superior quality of life for patients...
  11. pmc A novel role for histone deacetylase 6 in the regulation of the tolerogenic STAT3/IL-10 pathway in APCs
    Fengdong Cheng
    Department of Immunology and Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612
    J Immunol 193:2850-62. 2014
    ..The additional demonstration that a selective HDAC6 inhibitor disrupts this STAT3/IL-10 tolerogenic axis points to HDAC6 as a novel molecular target in APCs to overcome immune tolerance and tips the balance toward T cell immunity...
  12. pmc Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
    Asmita Mishra
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Am J Hematol 88:566-70. 2013
    ..Our data validate the prognostic value of the proposed IPSS-R and show that its refined IPSS prognostic discrimination can be applied to actively treated patients...
  13. doi request reprint Autoimmune diseases and myelodysplastic syndromes
    Rami S Komrokji
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Am J Hematol 91:E280-3. 2016
    ..011). Patient groups did not differ in response to azacitidine or lenalidomide treatment. Autoimmune diseases are prevalent among MDS patients. MDS patients with autoimmune diseases have better OS and less AML transformation...
  14. doi request reprint Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison
    Kristin M Phillips
    Mental Health and Behavioral Sciences, James A Haley Veterans Hospital, Tampa, FL, USA
    Support Care Cancer 21:1097-103. 2013
    ..Tyrosine kinase inhibitors (TKIs) are now standard treatment for chronic myeloid leukemia (CML). While TKIs have less toxicity than previous treatments, they have side effects that can impact quality of life (QOL)...
  15. doi request reprint Second Myeloid Malignancies in a Large Cohort of Patients With Chronic Lymphocytic Leukemia: A Single Institution Experience
    Julio C Chavez
    Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL Electronic address
    Clin Lymphoma Myeloma Leuk 15:S14-8. 2015
    ..Clinicians should understand the leukemogenicity of fludarabine or alkylator-based treatments when considering treatments for patients with CLL...
  16. doi request reprint Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemia
    Julio C Chavez
    Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, United States Electronic address
    Leuk Res 47:78-83. 2016
    ..The most common nonhematologic toxicity was infection (29% of patients). Lenalidomide combined with rituximab showed activity in heavily treated refractory CLL with an acceptable toxicity profile. ..
  17. doi request reprint Increased genomic instability may contribute to the development of kinase domain mutations in chronic myeloid leukemia
    Kendra Sweet
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA
    Int J Hematol 100:567-74. 2014
    ..0007, P = 0.235). Median PFS in patients with single versus compound or double mutations was not reached versus 10 months (P = 0.014). We conclude that T315I, P-loop, and compound mutations may worsen prognosis in CML...
  18. pmc Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cells
    Fengdong Cheng
    Department of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
    Mol Immunol 60:44-53. 2014
    ..This dynamic interaction results in dynamic changes in the expression of IL-10 and might help to explain the intrinsic plasticity of the APC to determine T-cell activation versus T-cell tolerance...
  19. doi request reprint Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes
    Rami S Komrokji
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA
    Am J Hematol 87:1006-9. 2012
    ..8; 95% CI 0.6-0.9; P = 0.004). Our findings indicate that hypoalbuminemia is an independent prognostic biomarker that may serve as a surrogate representative of disease biology or comorbidities in patients with MDS...
  20. pmc Stat3 inhibition augments the immunogenicity of B-cell lymphoma cells, leading to effective antitumor immunity
    Fengdong Cheng
    Departments of Malignant Hematology, Drug Discovery, and Hematopathology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Res 72:4440-8. 2012
    ..Our findings therefore indicate that Stat3 inhibition may represent a therapeutic strategy to overcome tolerance to tumor antigens and elicit a strong immunity against MCL and other B-cell malignancies...
  21. pmc Potentiation of Nilotinib-mediated cell death in the context of the bone marrow microenvironment requires a promiscuous JAK inhibitor in CML
    Rajesh R Nair
    Molecular Oncology Program, H Lee Moffitt Cancer Center, Tampa, FL, USA
    Leuk Res 36:756-63. 2012
    ..Finally, we demonstrate that in patient-derived primitive leukemic cells, co-cultured with BM stromal cells, inhibition of BCR-ABL and JAK activity was a successful strategy to potentiate their elimination...
  22. doi request reprint A close association of autoimmune-mediated processes and autoimmune disorders with chronic myelomonocytic leukemia: observation from a single institution
    Deniz Peker
    Department of Hematopathology and Laboratory Medicine, H Lee Moffitt Cancer Center and Research Institute, Tampa, Fla, USA
    Acta Haematol 133:249-56. 2015
    ..4%), although there was no statistical significance (p = 0.334). A multicenter large cohort study of CMML with AID is recommended to illustrate the molecular relationship between the two distinct groups...
  23. pmc Stat3 contributes to resistance toward BCR-ABL inhibitors in a bone marrow microenvironment model of drug resistance
    Nadine N Bewry
    Molecular Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33613, USA
    Mol Cancer Ther 7:3169-75. 2008
    ....
  24. pmc Histone deacetylase 11: A novel epigenetic regulator of myeloid derived suppressor cell expansion and function
    Eva Sahakian
    Department of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States
    Mol Immunol 63:579-85. 2015
    ....
  25. pmc Histone deacetylase inhibitor LAQ824 augments inflammatory responses in macrophages through transcriptional regulation of IL-10
    Hongwei Wang
    Department of Immunology and Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL 33613, USA
    J Immunol 186:3986-96. 2011
    ....
  26. pmc Phase II study of CD4+-guided pentostatin lymphodepletion and pharmacokinetically targeted busulfan as conditioning for hematopoietic cell allografting
    Mohamed A Kharfan-Dabaja
    Department of Blood and Marrow Transplantation, Moffitt Cancer Center, Tampa, FL 33612, USA
    Biol Blood Marrow Transplant 19:1087-93. 2013
    ..Two-year PFS was 55%, and OS was 68%. This regimen ensures durable engraftment, is effective against persistent disease, and results in relatively low mortality from causes other than relapse...
  27. ncbi request reprint Circumventing immune tolerance through epigenetic modification
    Jason A Dubovsky
    Department of Immunology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Curr Pharm Des 16:268-76. 2010
    ..Here we summarize recent findings on cancer-induced T-lymphocyte tolerance and discuss a novel "vaccinate-induce" strategy conceived to counteract these effects at an epigenetic level...
  28. pmc Enhanced CD8 T cell cross-presentation by macrophages with targeted disruption of STAT3
    Jason Brayer
    Department of Immunology and Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, United States
    Immunol Lett 131:126-30. 2010
    ..Targeting STAT3 signaling represents therefore an enticing strategy to augment CTL responses in the tumor-bearing host...
  29. ncbi request reprint Signaling networks associated with BCR-ABL-dependent transformation
    Lori A Hazlehurst
    Molecular Oncology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612, USA
    Cancer Control 16:100-7. 2009
    ..The fusion protein BCR-ABL results in constitutive tyrosine kinase activity. It also affects downstream targets as well as the subcellular location of the normally tightly regulated Abl tyrosine kinase...
  30. doi request reprint A case of acute basophilic leukemia arising from chronic myelogenous leukemia with development of t(7;8)(q32;q13)
    Joseph Pidala
    H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida 33612 9416, USA
    Cancer Genet Cytogenet 182:46-9. 2008
    ..A case is presented of ABL arising from chronic myelogenous leukemia with development of t(7;8)(q32;q13). Discussion includes a literature review...
  31. pmc WT1 vaccination in AML and MDS: A pilot trial with synthetic analog peptides
    Jason Brayer
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, Florida
    Am J Hematol 90:602-7. 2015
    ..Our WT1 vaccine was well-tolerated. The clinical benefit that we observed in several patients suggests engagement of a protective immune response, indicating a need for further trials...
  32. pmc Genomic aberrations deletion 11q and deletion 17p independently predict for worse progression-free and overall survival after allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia
    Julio C Chavez
    Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, USA
    Leuk Res 38:1165-72. 2014
    ..Presence of del (11q), del(17p), or progressive disease at HCT are independent predictors of worse PFS and OS. New strategies are needed to improve survival outcomes in CLL associated with poor risk cytogenetics...
  33. doi request reprint The one-two punch: combination treatment in chronic myeloid leukemia
    Kendra L Sweet
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, 13131 Magnolia Drive, 3 East, Rm 3056H, Tampa, FL 33612, United States
    Crit Rev Oncol Hematol 88:667-79. 2013
    ..This review examines the pathways, molecular targets, and potential new therapeutics that, with TKIs, may provide an effective "one-two punch" to cure CML...
  34. doi request reprint Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia
    Celeste Bello
    H Lee Moffitt Cancer, 12901 Magnolia Drive, FOB3, Tampa, FL 33612, USA
    Expert Rev Clin Immunol 7:295-300. 2011
    ..This article will review some of the key clinical studies that led to the drug's approval, current recommended usage of the drug and significant future directions...
  35. pmc Developing strategies in the immunotherapy of leukemias
    Jason B Brayer
    Malignant Hematology Program, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 20:49-59. 2013
    ..Partly from studying the nuances of the curative potential of stem cell transplant, we have come to appreciate the relevance of the immune response and the potential of immunotherapy...
  36. doi request reprint Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data
    Rami S Komrokji
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Clin Lymphoma Myeloma Leuk 11:257-60. 2011
    ..Diffuse large B-cell non-Hodgkin lymphoma (DLBCL) outcome in the United States has not been reported outside the context of clinical trials...
  37. doi request reprint Early switch in tyrosine kinase inhibitor therapy for patients with chronic myeloid leukemia: An emerging clinical question
    Kendra Sweet
    H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Crit Rev Oncol Hematol 103:99-108. 2016
    ..We also review completed and ongoing clinical studies involving a switch in frontline therapy for patients with CML, including those with a treatment-free remission phase. ..
  38. pmc Role of tyrosine-kinase inhibitors in myeloproliferative neoplasms: comparative lessons learned
    Javier Pinilla-Ibarz
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Onco Targets Ther 9:4937-57. 2016
    ..Here, we discuss the role of tyrosine-kinase inhibitors in the current MPN-treatment landscape. ..
  39. doi request reprint Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia
    Mohamed A Kharfan-Dabaja
    Division of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center, University of South Florida, Tampa, Florida 33612, USA
    Cancer 113:897-906. 2008
    ..Such a strategy could minimize unnecessary chemotoxicity in patients with favorable prognosis CLL, while reserving more aggressive therapy, including allogeneic hematopoietic cell transplantation, for patients with poor-risk features...
  40. doi request reprint Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens
    Samantha L Price
    Department of Pharmacy, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Leuk Res 35:301-4. 2011
    ..2% for MEC (P=0.09), with median OS of 11 and 4.5 months, respectively (P=0.07). In first relapse, CR was 36.8% and 25.9% (P=0.35) and median OS was 6.7 and 6.7 months, respectively (P=0.87). Our data support use of CLAG for RR-AML...
  41. ncbi request reprint Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia
    Estrella Carballido
    Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 19:54-67. 2012
    ..The vast majority of patients with relapsed or refractory CLL carry poor prognostic features, which are strong predictors of shorter overall survival and resistance to first-line treatment, particularly fludarabine-based regimens...
  42. ncbi request reprint Treatment of relapsed or refractory chronic lymphocytic leukemia
    Marays Veliz
    Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 33612, USA
    Cancer Control 19:37-53. 2012
    ..Recent advances in the treatment of chronic lymphocytic leukemia (CLL) have moved beyond the traditional use of alkylating agents and purine analogs into regimens combining these two chemotherapy classes with monoclonal antibodies...
  43. pmc A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer
    Elizabeth R Remily-Wood
    Molecular Oncology and Proteomics, H Lee Moffitt Cancer Center, Tampa, FL 33612, USA
    Proteomics Clin Appl 5:383-96. 2011
    ..moffitt.org/QUAD/, facilitates widespread implementation of quantitative mass spectrometry in cancer biology and clinical research through sharing of methods and reagents for monitoring protein expression and modification...
  44. pmc Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
    Mohamed A Kharfan-Dabaja
    Department of Blood and Marrow Transplantation, H Lee Moffitt Cancer Center, Tampa, Florida Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, Florida Electronic address
    Biol Blood Marrow Transplant 22:2117-2125. 2016
    ..These recommendations highlight the rapidly changing treatment landscape of CLL. Newer therapies have disrupted prior paradigms, and allo-HCT is now relegated to later stages of relapsed or refractory CLL...
  45. doi request reprint NCCN and ELN: What do the guidelines tell us?
    Kendra Sweet
    Moffitt Cancer Center, Tampa, FL, United States Electronic address
    Best Pract Res Clin Haematol 29:264-270. 2016
    ..With adherence to the recommendations proposed by the NCCN and ELN, we can expect to continue to see excellent outcomes for our patients with CML...
  46. pmc Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
    Josephine Emole
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
    Biologics 10:23-31. 2016
    ..The pharmacology, efficacy, and safety of nilotinib are critically evaluated. Patient-related issues, including tolerance, drug interactions, and quality of life issues are also examined. ..
  47. doi request reprint An update on current and prospective immunotherapies for chronic lymphocytic leukemia
    Josephine N Emole
    Department of Malignant Hematology, H Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL 33612, USA
    Immunotherapy 7:455-66. 2015
    ..Immunotherapeutic strategies can also be combined with chemotherapy to improve response rates in this incurable disease. In this review, we evaluate current and future immune-based options in the treatment of CLL. ..
  48. ncbi request reprint Front-line therapy for chronic lymphocytic leukemia
    Sheetal Desai
    Department of Pharmacy, H Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USA
    Cancer Control 19:26-36. 2012
    ..Improvements in the identification of prognostic markers for CLL, as well as novel combinations for chemoimmunotherapy regimens, have improved the outcome for patients with CLL...
  49. ncbi request reprint Histone deacetylase inhibition improves dendritic cell differentiation of leukemic blasts with AML1-containing fusion proteins
    Anja Moldenhauer
    Institute for Transfusion Medicine and Immunehaematology, Campus Virchow Klinikum, Charite Universitatsmedizin Berlin, Augustenburger Platz 1, 13353 Berlin, Germany
    J Leukoc Biol 76:623-33. 2004
    ..This model system suggests that the Hdi supports the in vitro differentiation of DC from leukemic blasts with AML1-containing fusion proteins...
  50. ncbi request reprint Novel targeted and immunotherapeutic strategies in chronic myeloid leukemia
    Joseph Schwartz
    Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Semin Hematol 40:87-96. 2003
    ..Other strategies target vascular endothelial growth factor (VEGF) and heat shock protein 90 (Hsp90) inhibitors or make use of CML-derived dendritic cells (DC)...